Copy to clipboard 
Amplitude Surgical reported FY1Q19 revenue of €19.5MM (USD $22.6MM) for the period ending September 30, 2018, an increase of +7.4% vs. FY1Q18. International sales growth complemented continued momentum in France. More than 50% of the revenue generated from the company’s NOVASTEP foot and ankle products came from international markets. Focus on U.S. market development is beginning to gain traction, as the company began making sales with the first implant of the ATOMIC knee prosthesis in September 2018.
Revenue from distributors increased by more than 50%, though leadership noted that this group’s performance is cyclical. Sales from subsidiaries slowed compared to FY1Q18, but two key markets, Australia and Brazil, grew in the mid to high single-digits.
ORTHOWORLD estimates quarter segment sales and growth on an as-reported basis as follows.
| FY1Q19 | FY1Q18 | $ Change | % Change | |
| Joint Reconstruction | $21.7 | $20.9 | $0.9 | 4.1% |
| Knees | $11.9 | $11.3 | $0.7 | 5.9% |
| Hips | $8.5 | $8.4 | $0.1 | 0.7% |
| Extremities | $1.3 | $1.2 | $0.1 | 12.3% |
| Arthroscopy / Soft Tissue Repair | $0.7 | n/a | n/a | n/a |
| Orthobiologics | $0.2 | $0.2 | $0.0 | 7.4% |
| Total | $22.6 | $21.1 | $1.6 | 7.4% |
*Amplitude entered the Arthroscopy/Soft Tissue Repair segment in December 2017.
Amplitude’s revenue by geographic region is as follows.
| Geographic Region | FY1Q19 | FY1Q18 | $ Change | % Change |
| France | $13.48 | $12.49 | $1.0 | 7.9% |
| International | $9.1 | $8.6 | $0.6 | 6.6% |
| Subsidiaries | $6.80 | $7.03 | -$0.2 | -3.2% |
| Distributors | $2.33 | $1.54 | $0.8 | 51.4% |
| Total | $22.6 | $21.1 | $1.6 | 7.4% |
Sources: Amplitude Surgical; ORTHOWORLD estimates. All revenue figures presented in USD $MM.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Amplitude Surgical reported FY1Q19 revenue of €19.5MM (USD $22.6MM) for the period ending September 30, 2018, an increase of +7.4% vs. FY1Q18. International sales growth complemented continued momentum in France. More than 50% of the revenue generated from the company’s NOVASTEP foot and ankle products came from international markets. Focus...
Amplitude Surgical reported FY1Q19 revenue of €19.5MM (USD $22.6MM) for the period ending September 30, 2018, an increase of +7.4% vs. FY1Q18. International sales growth complemented continued momentum in France. More than 50% of the revenue generated from the company’s NOVASTEP foot and ankle products came from international markets. Focus on U.S. market development is beginning to gain traction, as the company began making sales with the first implant of the ATOMIC knee prosthesis in September 2018.
Revenue from distributors increased by more than 50%, though leadership noted that this group’s performance is cyclical. Sales from subsidiaries slowed compared to FY1Q18, but two key markets, Australia and Brazil, grew in the mid to high single-digits.
ORTHOWORLD estimates quarter segment sales and growth on an as-reported basis as follows.
| FY1Q19 | FY1Q18 | $ Change | % Change | |
| Joint Reconstruction | $21.7 | $20.9 | $0.9 | 4.1% |
| Knees | $11.9 | $11.3 | $0.7 | 5.9% |
| Hips | $8.5 | $8.4 | $0.1 | 0.7% |
| Extremities | $1.3 | $1.2 | $0.1 | 12.3% |
| Arthroscopy / Soft Tissue Repair | $0.7 | n/a | n/a | n/a |
| Orthobiologics | $0.2 | $0.2 | $0.0 | 7.4% |
| Total | $22.6 | $21.1 | $1.6 | 7.4% |
*Amplitude entered the Arthroscopy/Soft Tissue Repair segment in December 2017.
Amplitude’s revenue by geographic region is as follows.
| Geographic Region | FY1Q19 | FY1Q18 | $ Change | % Change |
| France | $13.48 | $12.49 | $1.0 | 7.9% |
| International | $9.1 | $8.6 | $0.6 | 6.6% |
| Subsidiaries | $6.80 | $7.03 | -$0.2 | -3.2% |
| Distributors | $2.33 | $1.54 | $0.8 | 51.4% |
| Total | $22.6 | $21.1 | $1.6 | 7.4% |
Sources: Amplitude Surgical; ORTHOWORLD estimates. All revenue figures presented in USD $MM.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
